Home Molecular Imaging of Malignant Tumor Metabolism
Post
Cancel

Molecular Imaging of Malignant Tumor Metabolism

Purpose

To prospectively investigate the technical feasibility and performance of image fusion for whole-body diffusion-weighted imaging (wbDWI) and computed tomography (CT) to detect metastases using hybrid positron emission tomography/computed tomography (PET/CT) as reference standard.

Material and Methods

Fifty-two patients (60 ± 14 years; 18 women) with different malignant tumor disease examined by PET/CT for clinical reasons consented to undergo additional wbDWI at 1.5 Tesla. WbDWI was performed using a diffusion-weighted single-shot echo-planar imaging during free breathing. Images at b = 0 s/mm 2 and b = 700 s/mm 2 were acquired and apparent diffusion coefficient (ADC) maps were generated. Image fusion of wbDWI and CT (from PET/CT scan) was performed yielding for wbDWI/CT fused image data. One radiologist rated the success of image fusion and diagnostic image quality. The presence or absence of metastases on wbDWI/CT fused images was evaluated together with the separate wbDWI and CT images by two different, independent radiologists blinded to results from PET/CT. Detection rate and positive predictive values for diagnosing metastases was calculated. PET/CT examinations were used as reference standard.

Results

PET/CT identified 305 malignant lesions in 39 of 52 (75%) patients. WbDWI/CT image fusion was technically successful and yielded diagnostic image quality in 73% and 92% of patients, respectively. Interobserver agreement for the evaluation of wbDWI/CT images was κ = 0.78. WbDWI/CT identified 270 metastases in 43 of 52 (83%) patients. Overall detection rate and positive predictive value of wbDWI/CT was 89% (95% CI, 0.85–0.92) and 94% (95% CI, 0.92–0.97), respectively.

Conclusion

WbDWI/CT image fusion is technically feasible in a clinical setting and allows the diagnostic assessment of metastatic tumor disease detecting nine of 10 lesions as compared with PET/CT.

Whole-body (wb) positron emission tomography (PET) is playing an important role in staging of cancer providing functional information on tumor metabolism. The main limitation of PET is the poor spatial resolution, which has been overcome with the introduction of dual-modality PET/computed tomography (CT) imaging . The combination of metabolic and anatomical image data as dual-modality scanners have markedly increased lesion localization and diagnostic accuracy compared to both modalities as standalone applications .

Malignant lesions are not only characterized by pathologic metabolism (eg, high glucose uptake), which is used for 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG)-PET imaging, but also by higher cellularity consistent with restriction of water diffusion. Diffusion-weighted imaging (DWI) allows the measurement of water diffusion on a molecular level and is able to depict malignant lesions as areas of impeded diffusion. DWI has a great potential for tumor imaging and its value in various malignancies has been reported in several studies . Similar to PET imaging, DWI lacks sufficient anatomical information, due to low signal of physiologic anatomic structures. Therefore the capability of wbDWI is usually investigated together with magnetic resonance imaging (MRI) providing anatomical information. However, it is not evident yet, if the molecular information derived from wbDWI may potentially replace PET when evaluated under the same prerequisites namely CT imaging.

Get Radiology Tree app to read full this article<

Material and methods

Patients

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

PET/CT

Get Radiology Tree app to read full this article<

wbDWI

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Image Post Processing

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Image Analysis

Get Radiology Tree app to read full this article<

PET/CT

Get Radiology Tree app to read full this article<

wbDWI/CT: image quality

Get Radiology Tree app to read full this article<

wbDWI/CT: detection of malignancy

Get Radiology Tree app to read full this article<

Statistical Analysis

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Results

Patients

Get Radiology Tree app to read full this article<

PET/CT

Get Radiology Tree app to read full this article<

Table 1

Lesion-based Detection Rates and Positive Predictive Values for Detecting Metastases by wbDWI/CT Image Fusion, wbDWI, and CT Images using PET/CT as the Reference

Organs Number of Metastases Detection Rate PPV PET/CT wbDWI/CT wbDWI/CT(%) TP FP FN (%) (%) Liver 75 71 5 4 95 (0.89–1.00) 93 (0.87–0.99) Lung 69 66 1 3 96 (0.90–1.00) 99 (0.95–1.00) Lymph nodes 122 104 6 18 85 (0.79–0.92) 95 (0.90–0.99) Pancreas 2 2 0 0 100 (0.75–1.00) 100 (0.83–1.00) Intestinal tract 5 4 0 1 80 (0.35–1.00) 100 (0.88–1.00) Urogenital system 6 2 2 4 33 (0–0.79) 50 (0–1.00) Spleen 2 0 0 2 0 0 Soft tissue 11 11 1 0 100 (0.95–1.00) 92 (0.72–1.00) Skeletal system 9 6 1 3 67 (0.30–1.00) 86 (0.53–1.00) Central nervous system 4 4 0 0 100 (0.88–1.00) 100 (0.88–1.00) Total 305 270 16 35 89 (0.85–0.92) 94 (0.92–0.97)

FN, false negative; FP, false positive; PET/CT, positron emission tomography/computed tomography; PPV, positive predictive value; TP, true positive; wbDWI/CT, whole-body diffusion-weighted imaging/CT.

Numbers in parentheses are 95% confidence intervals.

Get Radiology Tree app to read full this article<

Image Quality

Get Radiology Tree app to read full this article<

Table 2

Image Quality Analyses of Fused wbDWI/CT Images

Fusion Quality of wbDWI/CT Diagnostic Image Quality of wbDWI/CT as compared to PET/CT Poor image fusion in 14 /52 (26.9) Worse and of nondiagnostic quality in 4/52 (7.7) Satisfactory image fusion in 34/52 (65.4) Worse but of diagnostic quality in 41/52 (78.8) Correct image fusion in 4/52 (7.7) Equal quality in 7/52 (13.5)

wbDWI, whole-body diffusion-weighted imaging.

Numbers in parentheses are percentages.

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

wbDWI/CT: Detection of malignancy

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Figure 1, A 57-year-old patient with a pancreatic adenocarcinoma. Whole-body diffusion-weighted images (wbDWi) with b-values of 0 (a) and 700 s/mm 2 (b) and fused wbDWI/computed tomography (CT) image (c) demonstrate hyperintense lesion in liver segment VI ( arrow ) graded as metastases. (d) PET/CT did not show any liver lesion resulting in a false-negative finding. In this case however, imaging follow-up and adjacent biopsy confirmed the lesion to be metastasis.

Figure 2, A 36-year-old male patient who suffers from a gastrointestinal stroma tumor of the stomach and peritoneal metastases. Whole-body diffusion-weighted-imaging (wbDWI) images with b-values of 0 (a) and 700 s/mm 2 (b) and fused wbDWI/computed tomography (CT) image (c) show hyperintense gastrointestinal stroma tumor of the stomach ( arrowheads ) and adjacent hyperintense peritoneal metastasis ( small arrow ). (d) These findings were also seen on positron emission tomography (PET)/CT. wbDWI images (a,b) and wbDWI/CT showed an additional hyperintense lesion adjacent to the liver ( large arrow ) interpreted as peritoneal metastasis. This lesion was not confirmed by PET/CT and was considered as a false-positive finding (d) .

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Discussion

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Image Quality

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Detection of Malignancy

Liver, lung, and lymph nodes

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Intestinal tract, soft tissue, skeletal system, and central nervous system

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Pancreas, spleen, and urogenital system

Get Radiology Tree app to read full this article<

Limitations

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Conclusion

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

References

  • 1. Beyer T., Townsend D.W., Blodgett T.M.: Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 2002; 46: pp. 24-34.

  • 2. Hany T.F., Steinert H.C., Goerres G.W., et. al.: PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002; 225: pp. 575-581.

  • 3. Pelosi E., Messa C., Sironi S., et. al.: Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004; 31: pp. 932-939.

  • 4. Low R.N., Gurney J.: Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging 2007; 25: pp. 848-858.

  • 5. Komori T., Narabayashi I., Matsumura K., et. al.: 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 2007; 21: pp. 209-215.

  • 6. Stecco A., Romano G., Negru M., et. al.: Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: comparison with positron emission tomography computed tomography (PET-CT) in a pilot study. Radiol Med 2009; 114: pp. 1-17.

  • 7. Sakurada A., Takahara T., Kwee T.C., et. al.: Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol 2009; 19: pp. 1461-1469.

  • 8. Nakanishi K., Kobayashi M., Nakaguchi K., et. al.: Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 2007; 6: pp. 147-155.

  • 9. Glazer G.M., Gross B.H., Quint L.E., et. al.: Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985; 144: pp. 261-265.

  • 10. Dorfman R.E., Alpern M.B., Gross B.H., et. al.: Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 1991; 180: pp. 319-322.

  • 11. Whittaker C.S., Coady A., Culver L., et. al.: Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review. Radiographics 2009; 29: pp. 759-774. discussion 774–758

  • 12. Landis J.R., Koch G.G.: An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977; 33: pp. 363-374.

  • 13. Wolz G., Nomayr A., Hothorn T., et. al.: Anatomical accuracy of interactive and automated rigid registration between X-ray CT and FDG-PET. Nuklearmedizin 2007; 46: pp. 43-48.

  • 14. Murtz P., Krautmacher C., Traber F., et. al.: Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla. Eur Radiol 2007; 17: pp. 3031-3037.

  • 15. Ruers T.J., Langenhoff B.S., Neeleman N., et. al.: Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002; 20: pp. 388-395.

  • 16. Antoch G., Vogt F.M., Freudenberg L.S., et. al.: Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290: pp. 3199-3206.

  • 17. Laurent V., Trausch G., Bruot O., et. al.: Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT. Eur J Radiol 2010; 75: pp. 376-383.

  • 18. Schmidt G.P., Baur-Melnyk A., Herzog P., et. al.: High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol 2005; 40: pp. 743-753.

  • 19. Pfannenberg C., Aschoff P., Schanz S., et. al.: Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007; 43: pp. 557-564.

  • 20. Uto T., Takehara Y., Nakamura Y., et. al.: Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology 2009; 252: pp. 247-254.

  • 21. Mori T., Nomori H., Ikeda K., et. al.: Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 2008; 3: pp. 358-364.

  • 22. Fischer M.A., Nanz D., Hany T., et. al.: Diagnostic accuracy of whole-bodyMRI/DWI image fusion for detection of malignant tumours: a comparison with PET/CT. Eur Radiol 2011; 21: pp. 246-255.

  • 23. Manfredi R., Pirronti T., Bonomo L., et. al.: Accuracy of computed tomography and magnetic resonance imaging in staging bronchogenic carcinoma. MAGMA 1996; 4: pp. 257-262.

  • 24. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et. al.: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343: pp. 254-261.

  • 25. Reinhardt M.J., Ehritt-Braun C., Vogelgesang D., et. al.: Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 2001; 218: pp. 776-782.

  • 26. Rosenbaum S.J., Lind T., Antoch G., et. al.: False-positive FDG PET uptake—the role of PET/CT. Eur Radiol 2006; 16: pp. 1054-1065.

  • 27. Vilanova J.C., Barcelo J.: Diffusion-weighted whole-body MR screening. Eur J Radiol 2008; 67: pp. 440-447.

  • 28. Lichy M.P., Aschoff P., Plathow C., et. al.: Tumor detection by diffusion-weighted MRI and ADC-mapping—initial clinical experiences in comparison to PET-CT. Invest Radiol 2007; 42: pp. 605-613.

  • 29. Takenaka D., Ohno Y., Matsumoto K., et. al.: Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009; 30: pp. 298-308.

  • 30. Rohren E.M., Provenzale J.M., Barboriak D.P., et. al.: Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003; 226: pp. 181-187.

  • 31. Kitajima K., Nakamoto Y., Okizuka H., et. al.: Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med 2008; 22: pp. 595-602.

  • 32. Okamoto K., Ito J., Ishikawa K., et. al.: Diffusion-weighted echo-planar MR imaging in differential diagnosis of brain tumors and tumor-like conditions. Eur Radiol 2000; 10: pp. 1342-1350.

  • 33. Duygulu G., Ovali G.Y., Calli C., et. al.: Intracerebral metastasis showing restricted diffusion: correlation with histopathologic findings. Eur J Radiol 2010; 74: pp. 117-120.

  • 34. Squillaci E., Manenti G., Di Stefano F., et. al.: Diffusion-weighted MR imaging in the evaluation of renal tumours. J Exp Clin Cancer Res 2004; 23: pp. 39-45.

  • 35. Lyng H., Haraldseth O., Rofstad E.K.: Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 2000; 43: pp. 828-836.

This post is licensed under CC BY 4.0 by the author.